These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 22103877)
1. Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives. de la Sierra A Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1585-91. PubMed ID: 22103877 [TBL] [Abstract][Full Text] [Related]
2. [Prevention of progression and regression of target organ damage. Future strategies]. de la Sierra A Rev Clin Esp; 2011 Mar; 211 Suppl 1():8-14. PubMed ID: 21458643 [TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
4. Recent changes in the landscape of combination RAS blockade. Epstein BJ; Smith SM; Choksi R Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020 [TBL] [Abstract][Full Text] [Related]
5. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Weber MA; Giles TD Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123 [TBL] [Abstract][Full Text] [Related]
6. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers? Volpe M QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630 [TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy. Giles TD Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312 [TBL] [Abstract][Full Text] [Related]
9. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice. Barrios V; Coca A; Escobar C; Enrique R; Rincón LM Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):159-66. PubMed ID: 22292872 [TBL] [Abstract][Full Text] [Related]
10. [The future of renin inhibition]. Uresin AY; Baran E Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475 [TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Ruilope LM Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118 [TBL] [Abstract][Full Text] [Related]
12. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient? de la Sierra A; Salazar J Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway. Heerspink HJ Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135 [TBL] [Abstract][Full Text] [Related]
14. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension]. Abassi Z; Armaly Z; Nakhoul F; Hoffman A Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632 [TBL] [Abstract][Full Text] [Related]
15. Aliskiren in the treatment of hypertension and organ damage. Riccioni G Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033 [TBL] [Abstract][Full Text] [Related]
16. The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence. Abdellatif AA Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):251-63. PubMed ID: 22292880 [TBL] [Abstract][Full Text] [Related]